Intuitive Surgical Stock Slides Over 10% as Slowing Growth Overshadows Earnings Beat

Intuitive Surgical (NASDAQ: ISRG) stock fell 10.9% in pre-market trading on July 17, 2026, after the company's second-quarter earnings report, while strong on its face, highlighted underlying concerns about slowing growth. Investors looked past the headline earnings beat to focus on a key deceleration in U.S. procedure volume and an unchanged full-year forecast.

Growth Concerns Spoil Earnings Beat

Intuitive Surgical reported stronger-than-expected Q2 2026 results, posting adjusted earnings of $2.80 per share on revenue of $2.89 billion. These figures surpassed analyst consensus estimates of $2.51 per share and $2.82 billion in revenue, according to Investing.com.

However, the market's attention was fixed on the company's core growth metric. U.S. procedure growth slowed to 12% in the second quarter, down from 14% in the first quarter. Management attributed the slowdown to factors including changes in ACA subsidies and deferred procedures. Furthermore, the company's non-GAAP gross margin of 70% was aided by a one-time $36 million tariff refund; excluding this, the margin would have been 68.7%.

Cautious Outlook and Valuation Pressure

Despite a strong first half, Intuitive Surgical maintained its full-year 2026 procedure growth forecast at a range of 13.5% to 15.5%, signaling an expected moderation in the second half of the year due to tougher year-over-year comparisons. This conservative guidance, combined with the U.S. slowdown, triggered a classic "sell-the-news" reaction from investors.

Ad

The sell-off is also compounded by the stock's high valuation. Trading at a price-to-earnings ratio near 49, well above its medical technology peers, Intuitive Surgical is vulnerable to any signs of decelerating growth. The broader market downturn and increasing competition from rivals like Medtronic and Johnson & Johnson are adding to the pressure on the stock's premium multiple.

Analyst Adjustments

Following the earnings release, several analysts adjusted their outlooks. Truist Securities, for example, maintained a Buy rating on the stock but lowered its price target to $510 from $580. This followed a series of pre-earnings target reductions from other firms that had already weighed on investor sentiment.

Management also noted persistent capital pressure in parts of Europe and uncertain policy timing in Japan and China, highlighting potential international headwinds for the remainder of the year.